Hansa Biopharma AB (publ) Total Liabilities

Hansa Biopharma AB (publ) (HNSBF) currently reports a total liabilities of $1.6B as of June 2026. That compares with $1.3B in the prior-year period — up 24.5% year over year. Use the charts on this page to explore Hansa Biopharma AB (publ)'s total liabilities history and peer comparisons.

Hansa Biopharma AB (publ)'s total liabilities increased from $1.3B to $1.6B — a 24.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Hansa Biopharma AB (publ) reported $1.6B in total liabilities as of June 2026. That compares with $1.3B in the prior-year period — up 24.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $1.6B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Hansa Biopharma AB (publ), and consider following HNSBF for alerts when major investors trade the stock.

Hansa Biopharma AB (publ) is classified in the Healthcare sector. On total liabilities, it currently shows $1.6B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HNSBF with unrelated industries.